Biblio
Graft-versus-host-disease prophylaxis with ATG or PTCY in patients with lymphoproliferative disorders undergoing reduced intensity conditioning regimen HCT from one antigen mismatched unrelated donor. Bone Marrow Transplant. 2024.
Haploidentical transplant with post-transplant cyclophosphamide for T-cell acute lymphoblastic leukemia: a report from the EBMT acute leukemia working party. Biol Blood Marrow Transplant. 2020.
Hematopoietic stem cell transplantation in multiple myeloma. A retrospective study of the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC). Biol Blood Marrow Transplant. 2015.
High Number of memory T cells is associated with higher risk Of acute GVHD after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2014.
. HLA-DP diversity is associated with improved response to SARS-Cov-2 vaccine in hematopoietic stem cell transplant recipients. iScience. 2023;26(5):106763.
. Human MAIT cells inhibit alloreactive T-cell responses and protect from acute graft-versus-host disease. JCI Insight. 2024.
Human-derived α1-antitrypsin is still efficacious in heavily pretreated patients with steroid-resistant gastrointestinal graft-versus-host disease. Biol Blood Marrow Transplant. 2020.
Impact of acute and chronic Graft-vs-Host Disease on human B-cell generation and replication. Blood. 2014.
Indole derivatives, microbiome and graft versus host disease. Curr Opin Immunol. 2021;70:40-47.
. Inferior Outcomes with Cyclosporine and Mycophenolate mofetil after Myeloablative Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2019.
Late Donor Bone Marrow Failure After Allogeneic Hematopoietic Stem Cell Transplantation. Transplantation. 2014;97(12):e75-e77.
. Late-onset noninfectious interstitial lung disease after allogeneic hematopoietic stem cell transplantation. Respir Med. 2014.
Matched related versus unrelated versus haploidentical donors for allogeneic transplantation in AML patients achieving first complete remission after two induction courses: a study from the ALWP/EBMT. Bone Marrow Transplant. 2023.
Mocravimod, a selective S1PR modulator in allogeneic hematopoietic stem cell transplantation for malignancy. Transplant Cell Ther. 2022.
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIb. The 2020 Preemptive Therapy Working Group Report. Transplant Cell Ther. 2021.
Operational tolerance after hematopoietic stem cell transplantation is characterized by distinct transcriptional, phenotypic, and metabolic signatures. Sci Transl Med. 2022;14(633):eabg3083.
Outcome after transplantation according to reduced intensity conditioning regimen in patients transplanted for myelofibrosis. Biol Blood Marrow Transplant. 2016.
A Personalized Approach to Guide Allogeneic Stem Cell Transplantation in Younger Adults with Acute Myeloid Leukemia. Blood. 2020.
Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. Lancet Haematol. 2020;7(2):e157-e167.
A prospective phase 2 clinical trial of a C5a complement inhibitor for acute GVHD with lower GI tract involvement. Bone Marrow Transplant. 2023.